Walnut Creek, CANCT07266805Now EnrollingIRB Ready

Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Clinical Trial in Walnut Creek, CA

Access cutting-edge acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) treatment through this phase 3 clinical trial at a research site in Walnut Creek. Study-provided care at no cost to qualified participants.

Sponsored by Pharvaris Netherlands B.V.

Quick Self-Assessment

See if you qualify for this Walnut Creek location

Preparing your pre-screening questions…

Expert Care in Walnut Creek

Access acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) treatment provided free

Apply for This Walnut Creek Location

Check if you qualify for this acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) clinical trial in Walnut Creek, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Walnut Creek

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Walnut Creek site if eligible
  4. 4Begin participation

About This Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Study in Walnut Creek

This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.

Sponsor: Pharvaris Netherlands B.V.

Who Can Participate

Inclusion Criteria

Provision of written informed consent
Male or female (sex at birth) aged ≥18 years
Diagnosis of AAE-C1INH
History of AAE-C1INH attacks prior to the Screening Visit:
Participants enrolling in Part 1 must have stable underlying disease of AAE-C1INH
The underlying condition can reasonably be expected to remain stable for the duration
Reliable access and ability to use available therapy to effectively manage AAE- C1INH attacks.
Female participants of childbearing potential must agree to the protocol-specified pregnancy testing and to be abstinent from heterosexual intercourse or to use an acceptable contraception method. Females of non-childbearing potential (prepubertal, surgically sterile, or postmenopausal with ≥ 12 months amenorrhea and postmenopausal FSH confirmation) are not required to use contraception during the study. • Capable of recording, without assistance, eDiary and ePRO data using an electronic device, as evidenced by the eDiary and ePRO training.

Exclusion Criteria

Participation in a clinical study with any other investigational drug within the last 30 days or within 5 half-lives of the investigational drug at the Screening Visit (whichever is longer).
Participants who have previously received prophylactic therapy but have stopped can participate in this study provided the last dose of the treatment was received prior to the timepoint before the Screening Visit
Any females who are pregnant, plan to become pregnant, or are currently breast-feeding
Abnormal hepatic function
Moderate or severe renal impairment
Any clinically significant comorbidity or systemic dysfunction that would interfere with the participant's safety or ability to participate in the study.
History of epilepsy and/or other significant neurological diseases
Any clinically significant and uncontrolled gastrointestinal dysfunction that may impact study drug absorption
Evidence of current alcohol or drug abuse
Use of medications that are moderate and strong inhibitors of cytochrome P450 (CYP) 3A4, or strong inducers of CYP3A4 within the last 30 days or within 5 half-lives (whichever is longer) at the time of the Screening Visit
Known hypersensitivity to deucrictibant or any of the excipients of the study drug
Use of angiotensin-converting enzyme inhibitors or any estrogen-containing medications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Walnut Creek?

Yes, this clinical trial (NCT07266805) has an active research site in Walnut Creek, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Treatment Options in Walnut Creek, CA

If you're searching for acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) treatment options in Walnut Creek, CA, this clinical trial (NCT07266805) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Walnut Creek research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acquired angioedema due to c1-inhibitor deficiency (aae-c1-inh) clinical trials near you to find additional studies recruiting in your area.

More Erectile Dysfunction Trials in Walnut Creek, CA

See all erectile dysfunction clinical trials recruiting in Walnut Creek — not just this study.

Browse Erectile Dysfunction Trials in Walnut Creek →

Browse More Trials by Condition

Erectile Dysfunction TrialsInterstitial Cystitis TrialsUrticaria TrialsAll Conditions →

Ready to Join in Walnut Creek?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Walnut Creek, CA